New York State Teachers Retirement System Sells 8,900 Shares of Boston Scientific Corporation $BSX

New York State Teachers Retirement System trimmed its stake in Boston Scientific Corporation (NYSE:BSX) by 0.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,208,251 shares of the medical equipment provider’s stock after selling 8,900 shares during the period. New York State Teachers Retirement System owned about 0.08% of Boston Scientific worth $115,207,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the stock. Vanguard Group Inc. grew its position in shares of Boston Scientific by 0.8% in the 3rd quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider’s stock worth $13,497,294,000 after buying an additional 1,115,337 shares during the period. Rathbones Group PLC boosted its stake in shares of Boston Scientific by 20.9% during the 4th quarter. Rathbones Group PLC now owns 2,759,657 shares of the medical equipment provider’s stock worth $263,133,000 after acquiring an additional 477,680 shares during the last quarter. Synergy Asset Management LLC grew its position in shares of Boston Scientific by 3,493.0% during the 3rd quarter. Synergy Asset Management LLC now owns 493,323 shares of the medical equipment provider’s stock valued at $48,297,000 after acquiring an additional 479,593 shares during the period. Gladstone Institutional Advisory LLC grew its position in shares of Boston Scientific by 39.5% during the 3rd quarter. Gladstone Institutional Advisory LLC now owns 51,884 shares of the medical equipment provider’s stock valued at $5,065,000 after acquiring an additional 14,700 shares during the period. Finally, Kepler Cheuvreux Suisse SA purchased a new stake in shares of Boston Scientific in the 3rd quarter worth $26,955,000. Institutional investors own 89.07% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on BSX. Robert W. Baird lowered their target price on Boston Scientific from $86.00 to $78.00 and set an “outperform” rating on the stock in a research report on Thursday, April 23rd. Wells Fargo & Company reduced their price target on Boston Scientific from $94.00 to $75.00 and set an “overweight” rating for the company in a research report on Thursday, April 23rd. Argus raised Boston Scientific to a “strong-buy” rating in a research report on Thursday, February 26th. Oppenheimer set a $90.00 price objective on Boston Scientific in a research note on Thursday, April 23rd. Finally, UBS Group dropped their price objective on Boston Scientific from $120.00 to $105.00 and set a “buy” rating for the company in a research note on Tuesday, March 17th. One research analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $93.91.

Insider Activity

In related news, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the transaction, the chief executive officer owned 1,411,735 shares in the company, valued at $131,983,105.15. This trade represents a 10.23% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders own 0.34% of the company’s stock.

Boston Scientific Stock Performance

Boston Scientific stock opened at $57.69 on Friday. The company’s 50-day moving average price is $67.06 and its 200-day moving average price is $84.72. The company has a quick ratio of 1.08, a current ratio of 1.62 and a debt-to-equity ratio of 0.46. The company has a market cap of $85.74 billion, a PE ratio of 24.14, a price-to-earnings-growth ratio of 1.05 and a beta of 0.78. Boston Scientific Corporation has a twelve month low of $56.05 and a twelve month high of $109.50.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, beating analysts’ consensus estimates of $0.79 by $0.01. The firm had revenue of $5.20 billion during the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.68%. The firm’s revenue for the quarter was up 11.6% compared to the same quarter last year. During the same quarter last year, the firm earned $0.75 EPS. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. On average, equities research analysts forecast that Boston Scientific Corporation will post 3.38 EPS for the current fiscal year.

Key Stories Impacting Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: New clinical data and procedure adoption: A Reuters note highlighted that a procedure using a Boston Scientific device outperformed drug therapy for a heart‑rhythm indication, supporting device demand and reimbursement relevance. This is a clear product/market tailwind if adoption continues. Procedure using Boston Scientific device tops medication
• Positive Sentiment: Supportive TV commentary: Jim Cramer said he thinks Boston Scientific “can come back,” a sentiment that can boost retail interest and short‑term buying flows. Jim Cramer on Boston Scientific
• Positive Sentiment: Institutional buying signal: Lone Pine Capital (Stephen Mandel) opened a new position, signaling selective hedge‑fund interest in BSX. Large manager activity can be supportive for the stock if it continues. Stephen Mandel opens new position
• Neutral Sentiment: Investor attention piece: Zacks flagged BSX as drawing investor attention, a sign of increased search/interest but not necessarily directional news. Monitor volume and follow‑through. Zacks: BSX attracting investor attention
• Neutral Sentiment: Ticker confusion: A GlobeNewswire item about Belo Sun (TSX: BSX) appears in feeds — note this is a different company and unrelated to Boston Scientific (NYSE: BSX). Don’t conflate the two. Belo Sun Provides Update (unrelated ticker)
• Neutral Sentiment: Market commentary roundup: Aggregated articles (MSN/Yahoo) are weighing bullish vs bearish views; these are useful for sentiment tracking but contain no single material disclosure. MSN: Wall Street bullish or bearish?
• Negative Sentiment: Class‑action filings and lead‑plaintiff deadline (May 4): Multiple law firms and plaintiff notices allege disclosure issues around U.S. electrophysiology sales and invite claims—this increases legal overhang and potential settlement risk. Monitor filings and reserve/expense guidance. Securities fraud lawsuit alert
• Negative Sentiment: Analyst downgrades and lower targets: Daiwa cut BSX to “hold” and at least one outlet reports an ~11% cut to the price target — these reduce near‑term analyst support and can pressure sentiment. Daiwa downgrade / analyst action
• Negative Sentiment: Fund selling and estimate cuts: Polen Capital disclosed it sold its stake citing competition concerns, and Erste Group trimmed FY2026/27 EPS forecasts — both items point to investor wariness on competitive pressure and margin/earnings outlook. Polen sold stake

Boston Scientific Company Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.